Summary
9.46 -0.08(-0.79%)10/04/2024
Precision Biosciences Inc (DTIL)
Precision Biosciences Inc (DTIL)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-0.94 | 4.82 | -4.06 | 3.45 | -33.97 | 2,829.97 | 25.07 | -45.79 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 9.46 | |
Open | 9.63 | |
High | 9.81 | |
Low | 9.22 | |
Volume | 62,530 | |
Change | -0.09 | |
Change % | -0.94 | |
Avg Volume (20 Days) | 63,774 | |
Volume/Avg Volume (20 Days) Ratio | 0.98 | |
52 Week Range | 0.28 - 19.43 | |
Price vs 52 Week High | -51.34% | |
Price vs 52 Week Low | 3,276.79% | |
Range | -1.82 | |
Gap Up/Down | -0.15 |
Fundamentals | ||
Market Capitalization (Mln) | 66 | |
EBIDTA | -66,426,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 17.67 | |
Book Value | 1.6880 | |
Earnings Per Share | -0.5610 | |
EPS Estimate Current Quarter | -0.5900 | |
EPS Estimate Next Quarter | -0.6100 | |
EPS Estimate Current Year | -0.6300 | |
EPS Estimate Next Year | -2.0500 | |
Diluted EPS (TTM) | -0.5610 | |
Revenues | ||
Profit Marging | -0.2691 | |
Operating Marging (TTM) | -0.2722 | |
Return on asset (TTM) | -0.1015 | |
Return on equity (TTM) | -0.3844 | |
Revenue TTM | 118,036,000 | |
Revenue per share TTM | 2.0840 | |
Quarterly Revenue Growth (YOY) | 2.2640 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 24,285,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 5.1397 | |
Revenue Enterprise Value | 3.1554 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 60,767,300 | |
Shares Float | 50,658,665 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 10.62 | |
Institutions (%) | 49.39 |
10/03 07:01 EST - businesswire.com
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that the Company will present during a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference taking place October 8, 2024. Presentation Details: Date: October 8, 2024 Time: 11:00AM ET Format: F.
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that the Company will present during a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference taking place October 8, 2024. Presentation Details: Date: October 8, 2024 Time: 11:00AM ET Format: F.
09/30 07:01 EST - businesswire.com
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that the Company submitted Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company's wholly owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by eliminati.
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that the Company submitted Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company's wholly owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by eliminati.
09/20 07:01 EST - businesswire.com
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that, on September 18, 2024, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Em.
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that, on September 18, 2024, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Em.
09/13 10:56 EST - zacks.com
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
09/11 09:52 EST - zacks.com
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
08/28 10:57 EST - zacks.com
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
The consensus price target hints at a 307.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
The consensus price target hints at a 307.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
08/09 07:01 EST - businesswire.com
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that its partner TG Therapeutics has received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) Application to investigate Azercabtagene Zapreleucel (aze.
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that its partner TG Therapeutics has received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) Application to investigate Azercabtagene Zapreleucel (aze.
08/08 06:00 EST - investorplace.com
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
08/01 09:25 EST - zacks.com
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
Precision BioSciences (DTIL) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of a loss of $0.77 per share. This compares to loss of $3 per share a year ago.
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
Precision BioSciences (DTIL) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of a loss of $0.77 per share. This compares to loss of $3 per share a year ago.
07/29 16:15 EST - businesswire.com
Precision BioSciences to Report Second Quarter Results on August 1, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCU.
Precision BioSciences to Report Second Quarter Results on August 1, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCU.
07/08 07:01 EST - businesswire.com
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California. Presentation Details: Date: Monday, July 15, 2024 Time: 9:30 AM PT Format: Company Presentation Webcast Registration: Link A live webcast of the.
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California. Presentation Details: Date: Monday, July 15, 2024 Time: 9:30 AM PT Format: Company Presentation Webcast Registration: Link A live webcast of the.
06/27 07:01 EST - businesswire.com
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024. “Our team is proud to share details from our.
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024. “Our team is proud to share details from our.
06/20 07:00 EST - businesswire.com
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural membe.
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural membe.
06/05 07:01 EST - businesswire.com
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster present.
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster present.
05/30 07:00 EST - businesswire.com
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024 Time: 1:30 pm – 1:55 pm ET Format.
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024 Time: 1:30 pm – 1:55 pm ET Format.
05/29 10:56 EST - zacks.com
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
05/20 01:38 EST - https://www.defenseworld.net
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/13 07:00 EST - businesswire.com
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. “In 2024, Precision is focused on strong execution as we advance our wholly owned Hepatitis B virus (HBV) and prim.
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. “In 2024, Precision is focused on strong execution as we advance our wholly owned Hepatitis B virus (HBV) and prim.
05/08 08:15 EST - businesswire.com
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership te.
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership te.